← All diseases Infectious diseases

Chronic hepatitis C

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchHighest evidence only (76)Meta-analysis (20)Treatment guideline (4)Phase 3 study (24)Randomized trial (14)Systematic review (14)Clinical trial (680)Review article (146)Early study (phase 1 or 2) (11)Case report (85)Laboratory or animal study (8)Commentary or editorial (53)Retracted publication (2) Studies currently recruiting participants only (15)

Filter

Publications and studies (1942)

• Low-Barrier Fibrosis Screening in Hepatitis C Treatment: The Decompensated Cirrhosis in Hepatitis C Evaluation Questionnaire. (2026/06/01) ♡
• LC3-Associated Phagocytosis in Hepatitis C Virus-Induced Fibrosis. (2026/06/01) ♡
• Resolved HBV Infection Is Not Associated With Liver-Related Outcomes in Survival Analysis of Caucasians After HCV Cure. (2026/06/01) ♡
• Observational, Post-marketing Surveillance of Safety and Effectiveness of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C. (2026/06/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The complexities of the pharmacotherapeutic management of chronic hepatitis C virus infection in hepatocellular carcinoma patients. (2026/06/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Health care costs associated with disease progression of untreated chronic hepatitis C in the United States. (2026/06/01) ♡
• An artificial intelligence model for prediction of hepatocellular carcinoma risk in patients with chronic hepatitis C. (2026/06/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. T cell dysfunction and metabolic disruption in chronic hepatitis C virus infection. (2026/06/01) ♡
• High prevalence of seronegative occult hepatitis C in high-risk individuals. (2026/06/01) ♡
• HCC-miR: A Simple, Noninvasive, and Sensitive Model for Early Diagnosis of HCV-Associated Hepatocellular Carcinoma. (2026/06/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Impact of Fatigue on Patient-Reported Outcomes and Work Productivity in Chronic Hepatitis B and C: Insights From a Multinational Registry Study. (2026/06/01) ♡
• Reelin level in serum-derived extracellular vesicles predicts regression of M2BPGi-defined liver fibrosis following hepatitis C virus eradication by direct-acting antiviral agents. (2026/05/30) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Antiviral therapy and the risk of extrahepatic malignancies in chronic hepatitis C: insights from recent evidence. (2026/05/30) ♡
• Hepatitis C virus can induce gene expression changes associated with hepatocarcinogenesis. (2026/05/29) ♡
• Association Between Hepatitis C Virus Infection and SYNTAX Score in Patients with ST-Segment Elevation Myocardial Infarction: A Propensity Score-Matched Analysis. (2026/05/28) ♡
• Chronic hepatitis C infection status among HCV-Ab positive patients above 50 years old in Anhui Province from 2004 to 2022. (2026/05/27) ♡
• Comorbidities Associated With Chronic Hepatitis C Among Medicaid Beneficiaries, 2016-2020. (2026/05/27) ♡
• The three-decade trajectory of hepatitis C burden among women of reproductive age in China: a retrospective and predictive study. (2026/05/21) ♡
• Simple model stratifies liver cancer risk in non-cirrhotic chronic hepatitis C patients after viral eradication. (2026/05/20) ♡
• From Discovery to Cure-Where Are We Now? Mortality Trends in Chronic Hepatitis C: An Analysis of CDC WONDER Database (1999-2023). (2026/05/20) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Robotic Resection of Caudate Lobe Hepatocellular Carcinoma. (2026/05/19) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Triple infection with pulmonary tuberculosis, chronic hepatitis C and systemic brucellosis in an HIV/AIDS patient: a case report from northwestern China. (2026/05/19) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Hypertensive Emergency and Brainstem Hemorrhage Temporally Associated With Intramuscular Epinephrine: A Case Report. (2026/05/18) ♡
• Towards hepatitis C elimination with integrated risk-based screening and decentralized care in Taiwan. (2026/05/15) ♡
• Liver stiffness by non-invasive tests predicts hepatocellular carcinoma and liver-related complications following viral eradication with direct-acting antivirals in chronic hepatitis C: a retrospective cohort study. (2026/05/14) ♡
• An unusual presentation of Hepatocellular Carcinoma: Isolated bile duct involvement without detectable hepatic mass. (2026/05/11) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Right Atrial Vegetation on a Chiari Network Presenting With Multifocal Pulmonary Lesions. (2026/05/10) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Reply to the comment on "High-normal and abnormal alanine transaminase levels linked to increased risk of hepatoma following treatment for chronic hepatitis C". (2026/05/09) ♡
• A Unified Histopathological Framework of Liver Fibrogenesis in Chronic Viral Hepatitis B, C and Coinfection. (2026/05/08) ♡
• Mapping HLA class I and II allele associations with hepatitis C related liver disease progression in an Egyptian cohort. (2026/05/07) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Splenic Marginal Zone Lymphoma as a Vascular-Appearing Mass in a Patient With Sustained Virologic Response to Hepatitis C Therapy. (2026/05/06) ♡
• Outcomes of Hepatitis C Virus Testing and Treatment at a Rural Safety Net Clinic in East Tennessee. (2026/05/04) ♡
• Safety and Drug-Drug Interaction Burden of Direct-Acting Antiviral Therapy for Hepatitis C: A Single-Center Community Hospital Analysis. (2026/05/04) ♡
• Pangenotypic Glecaprevir/Pibrentasvir Therapy for Chronic Hepatitis C in Children. (2026/05/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Correspondence on "A. Changes in liver stiffness and non-invasive markers in chronic hepatitis C virus patients with and without HIV co-infection following interferon-free antiviral treatment". (2026/05/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Hepatitis C Virus and Type 2 Diabetes: Mechanisms, Clinical Impact, and Post-DAA Management. (2026/05/01) ♡
• Influence of Schistosomiasis on Fibrosis Evolution After Interferon-Induced SVR in Chronic HCV Over a 12-Year Biopsy-Based Study. (2026/05/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Efficacy and Safety of 12-Week Coblopasvir/Sofosbuvir Regimen for Hepatitis C in Northwest China: A Multi-Center Prospective Study. (2026/05/01) ♡
• Novel Score Based on miRNA-106 b.5p Expression Signature and Routine Biomarkers for Early Detection of Hepatocellular Carcinoma among High-Risk Hepatitis C Virus Patients. (2026/05/01) ♡
• Lipid abnormalities in chronic viral hepatitis: associations and machine learning-enhanced prediction. (2026/04/30) ♡
• Long-term outcomes of patients with hepatitis C virus-related liver transplantation in a high-volume transplant center. (2026/04/29) ♡
• Changing Landscape of Chronic Liver Diseases in a Tertiary Level Hospital of Bangladesh Over the Last 10 Years. (2026/04/28) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Comment on "High-normal and abnormal alanine transaminase levels linked to increased risk of hepatoma following treatment for chronic hepatitis C". (2026/04/27) ♡
• OATP1B3 c.699G>A Predicts a 6.3-Fold Increased Risk of Hyperbilirubinemia During OPrD Therapy for HCV. (2026/04/27) ♡
• Investigation of Changes in Irisin and Nesfatin-1 Levels in Chronic Viral Hepatitis. (2026/04/23) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Hepatitis C Virus: An Overview of Its Chronic Impact on Liver Function, Metabolic Dysregulation, Inflammatory-Oxidative Pathogenesis and Epigenetic Memory. (2026/04/16) ♡
• Machine learning-based prediction of treatment response in comorbid hepatitis C patients receiving DAA therapy: a real-world study from Pakistan. (2026/04/13) ♡
• Efficacy and Safety of Direct-Acting Antivirals in Patients with Hepatitis C Infection: Nationwide Real-life Data from Türkiye. (2026/04/10) ♡
• Behavioural trajectories following DAA treatment for HCV among people with HIV: findings from an international consortium of prospective cohort studies. (2026/04/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Advanced Fibrosis and Cardiometabolic Risk Burden Increase Major Cardiovascular Events in Chronic Hepatitis C Patients With Steatotic Liver Disease After Viral Eradication. (2026/04/01) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.